China is not as big a player in the manufacturing of key ingredients used to make brand and generic medicines as previously ...

Leqembi approved by the EU for early-stage Alzheimer’s in patients with specific ApoE4 gene profile, marking a milestone in ...

Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the ...

The European Commission said Wednesday that it had given formal approval for Leqembi, a long-awaited new treatment for ...

The General Inspectorate of Health Activities (IGAS) has opened a clarification process regarding the marketing of the drug ...

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi ...

CHMP reversed its initial recommendation for the EC to not authorize the drug due to the risk of side effects like ARIA.

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

Cullinan Therapeutics (CGEM) announced that the European Medicines Agency, EMA, approved the Company’s Clinical Trial Application, CTA, for ...

As per Vantage Market Research, the Pharmaceutical Manufacturing Market is poised for growth due to various factors, such as ...

The antibody lecanemab is the first authorized therapy in Europe that targets the underlying process of Alzheimer's, rather than only treating symptoms.

The European Commission has for the first time approved an Alzheimer's therapy that targets the underlying disease processes.